Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly has emerged as one of Wall Street’s most exciting biotech stories, transforming from a steady pharmaceutical name into a dynamic growth machine. This shift isn’t fueled by empty hype but by ...

Eli Lilly and Co. and Purdue Strategic Ventures recently participated in a $12 million funding round to support a new remote lab platform aimed at significantly decreasing the time it takes to ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth stories—and it’s not just hype. Powered by blockbuster drugs for diabetes ...

At the same time, pharmaceutical companies leading the GLP-1 charge — particularly Eli Lilly (LLY) — are surging. In this post, I’ll break down what’s happening in the alcohol industry, the science ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 billion. This move has been done to expand the company’s neuroscience ...

(RTTNews) - Eli Lilly and Company (LLY), Tuesday announced an agreement regarding the acquisition of SiteOne Therapeutics, Inc., a private biotechnology company, for upto $1 billion in cash ...

Congratulations to the entire SiteOne family on acquisition by Eli Lilly announced this morning. It was an honor to serve as Exec Chair. Thanks to John Mulcahy, CEO, John Hunter, CSO, Diana Chung ...

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Navitas: "That one's done...I say take your money out that you put in and then you can ...

Eli Lilly: "I just think this is a decent level to start a position if you don't have any [buy, buy, buy!]." Stream Connecticut News for free, 24/7, wherever you are. Navitas: "That one's done ...